Abstract
Eighty-two patients with small cell lung cancer (SCLC), 32 with limited disease, were treated with alternating chemotherapy. Eight courses were administered at weekly intervals, and responding patients received radiotherapy to sites of bulk disease. Overall response rate was 76.8%. Overall median survival was 265 days, 408 days in patients with limited disease. The median symptom free period after chemotherapy was completed was 123 days. These results are comparable with those in reports of chemotherapy of longer duration and warrant the further investigation of short duration treatment in this disease.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adult
-
Aged
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Carcinoma, Small Cell / drug therapy*
-
Carcinoma, Small Cell / radiotherapy
-
Cyclophosphamide / administration & dosage
-
Doxorubicin / administration & dosage
-
Drug Administration Schedule
-
Etoposide / administration & dosage
-
Humans
-
Leucovorin / administration & dosage
-
Lung Neoplasms / drug therapy*
-
Lung Neoplasms / radiotherapy
-
Methotrexate / administration & dosage
-
Middle Aged
-
Time Factors
-
Vincristine / administration & dosage
Substances
-
Vincristine
-
Etoposide
-
Doxorubicin
-
Cyclophosphamide
-
Leucovorin
-
Methotrexate